rewirebio.iobenchmarks
Source

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 · Peer-reviewed

DOI: 10.1038/s41467-025-64153-z

The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model.

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Breast vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.954 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)1.000 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Lung vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.896 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 4 phenotypes of the median one-vs-rest AUROCs; FoundationOne Liquid CDx genes)0.958 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.983 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Breast vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.945 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; Full panel genes)1.000 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Lung vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.894 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 4 phenotypes of the median one-vs-rest AUROCs; Full panel genes)0.956 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.983 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Breast vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.919 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.999 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Lung vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.868 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 4 phenotypes of the median one-vs-rest AUROCs; Guardant360 CDx genes)0.940 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.974 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Breast vs all other classes, one-vs-rest, median of 25 replicates; Tempus xF genes)0.934 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail tempus xf (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; Tempus xF genes)1.000 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail tempus xf (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Lung vs all other classes, one-vs-rest, median of 25 replicates; Tempus xF genes)0.879 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail tempus xf (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 4 phenotypes of the median one-vs-rest AUROCs; Tempus xF genes)0.946 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail tempus xf (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; Tempus xF genes)0.970 unitlessRazavi et al. 2019 GRAIL targeted cfDNA cohort as used by Helzer et al. 2025 (198 samples)All Combined on grail tempus xf (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Bladder vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.953 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERneg vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.896 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERpos vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.959 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.969 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 9 phenotypes of the median one-vs-rest AUROCs; FoundationOne Liquid CDx genes)0.931 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NEPC vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.986 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NSCLC vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.850 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.984 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (RCC vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.900 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (SCLC vs all other classes, one-vs-rest, median of 25 replicates; FoundationOne Liquid CDx genes)0.878 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw foundationone (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Bladder vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.947 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERneg vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.867 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERpos vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.951 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; Full panel genes)0.967 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 9 phenotypes of the median one-vs-rest AUROCs; Full panel genes)0.921 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NEPC vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.971 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NSCLC vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.839 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.985 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (RCC vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.887 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (SCLC vs all other classes, one-vs-rest, median of 25 replicates; Full panel genes)0.873 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw full (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Bladder vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.914 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERneg vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.907 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (ERpos vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.960 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (healthy (Normal) vs all cancers, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.974 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (mean over 9 phenotypes of the median one-vs-rest AUROCs; Guardant360 CDx genes)0.926 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NEPC vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.985 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (NSCLC vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.838 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (Prostate vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.974 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (RCC vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.919 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)
All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)AUROC (SCLC vs all other classes, one-vs-rest, median of 25 replicates; Guardant360 CDx genes)0.860 unitlessUniversity of Wisconsin targeted cfDNA cohort (431 samples)All Combined on uw guardant360 (Helzer et al. 2025)

Claims

Statements this source supports, each with where in the source it was checked.

  • Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
  • related_result: ctdnalit-20261011-helzer2025-protocol-grail-full: Related result In silico mixing of GRAIL-cohort cancer and healthy reads (70% training, 30% validation; mixtures 50:50 to 1:99 at 100 M reads) showed all metrics losing AUROC as ctDNA fraction fell, with depth at all exons best; at 0.0001-0.001 ctDNA fraction many AUROCs approached 0.5. The values are shown only in Figure 6B and are not stored as results. (Results P15-P17; Figure 6; Methods P31)
  • Relevance of ctdnalit-20261011-helzer2025-protocol-grail-full to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, full panel: multinomial phenotype AUROC (ctdnalit-20261011-helzer2025-source-article: Results P5-P8; Methods P23-P31; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Table S1)
  • Relevance of ctdnalit-20261011-helzer2025-protocol-uw-full to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Helzer et al. 2025 UW cohort, full panel: multinomial phenotype AUROC (ctdnalit-20261011-helzer2025-source-article: Results P5-P8; Methods P23-P31; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Table S2)

Models, benchmarks and other records

Methods (14)

Configurations (14)

Protocols (8)

Datasets (2)

Evaluations (105)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

21 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive note
gzip -n -9 copy of the exact bytes in artifacts/helzer2025-article.xml.gz (CC BY 4.0)
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Archive sha256
d3f262037df5f2aabc36cbe9e3b80ea994319a32f56da881fc332f36381c5dc2
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_sha256

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12521513/fullTextXML
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1038/s41467-025-64153-z
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
CC-BY-4.0
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/xml
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-11T21:40:59Z
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Scope note
The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model.
Source metadata
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Original source ↗

No field-specific location recorded

Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
Retrieved: 2026-10-11T21:40:59Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.scope_note

Source artifact SHA-256: 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source retrieved and hashed for the 2026-10-11 plasma ctDNA literature pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnalit-20261011-helzer2025-source-article

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.1038/s41467-025-64153-z
artifact url
https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12521513/fullTextXML
version
Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
retrieved at
2026-10-11T21:40:59Z
artifact sha256
48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835
doi
10.1038/s41467-025-64153-z
publication status
peer_reviewed
licence
CC-BY-4.0
media type
application/xml
source locator
Full artifact bytes; per-record locators on each record. 'Pn' is the zero-based index of the <p> element in document order in this JATS XML, front matter included.
archive sha256
d3f262037df5f2aabc36cbe9e3b80ea994319a32f56da881fc332f36381c5dc2
archive note
gzip -n -9 copy of the exact bytes in artifacts/helzer2025-article.xml.gz (CC BY 4.0)
scope note
The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model.
Related records

    Suggest a correction